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In spite of the increasing significance, the origin of the tumour-associated non-tumour-
cell elements (tumour-associated fibroblasts and endothelium) has not been determined 
decisively. As it has recently been shown, one source of the tumour-associated stroma (TAS) 
is bone marrow-derived mesenchymal stem cells (BM-MSCs) which migrate into the solid 
tumour and there contribute to the establishment of TAS.  
Exogenously administered MSCs migrate and specifically localize into tumours. 
However, the effect of transplanted MSCs in term of tumour progression is still actively 
debated, since both tumour-promoting and tumour-moderating functions have been indicated. 
Tumour promotion by MSCs has been primarily attributed to their immunosuppressive 
function and neo-vascularisation promoting effect. All effects of MSCs in solid tumours can 
be explained by two mechanisms: 1) differentiation of the multipotent MSCs into tumour-
associated tissue elements such as fibroblasts, tumour-associated blood vessel endothelium 
and/or smooth muscle  or 2) MSCs are not stably associated with these sites, rather they affect 
tumorigenesis via producing various angiogenic (VEGF, PDGF, FGF), immunosuppressive 
(TGF- , IDO, IL-10, PGE2) and metastatic (CCL5) factors. These possibilities are not 
exclusive; however providing definite answer is difficult due to the lack of MSC specific 
molecular markers.   
Galectin-1 (Gal-1) is an immunosuppressive and pro-angiogenic member of the -
galactoside-binding lectin family, galectins. Immunosuppressive function of Gal-1 has been 
confirmed in a number of in vivo and in vitro studies. Targeted inhibition of Gal-1 function or 
expression in tumour cells provokes immune response against the tumour and subsequent 
tumour rejection. Also, Gal-1 has recently been implicated in growth and metastasis of solid 
tumours. Accordingly, high expression of Gal-1 in the tumour cells and/or in TAS indicates 
poor prognosis of the disease. Crucial role of Gal-1 in tumour angiogenesis has also been 
confirmed. Additionally, genetically engineered carcinoma-associated fibroblasts expressing 
low level of Gal-1 failed to help tumour progression. High level of Gal-1 expression has been 




It was previously shown that MSCs produce Gal-1 but functional studies revealed only 
the in vitro immunosuppressive role of MSC derived Gal-1. The effect of MSCs on the 
development of solid tumours and the key factors released by MSCs influencing tumour 
progression remained unknown. In order to elucidate these questions we addressed the 
following:  
 
1.)  What is the impact of Gal-1 produced by bone marrow derived MSCs on the growth, 
vascularisation and metastatic frequency of primary tumours in animal model? 
2.) How does the bone marrow MSC-derived Gal-1 influence the incidence of primary 
tumours and the survival of tumour bearing mice?  
3.) How can be sequestered the effect of MSC or tumour cell derived Gal-1 on the 







1. Isolation of MSCs  
2. Mammalian cell culturing                        
3. Characterisation of MSCs by flow cytometry                      
4. Characterisation of adipogenic and osteogenic differentiation property of MSCs  
5. Gal-1 gene silencing in MSCs by siRNS transfection                     
6. Mouse tumour models                        
7. SDS gel-electrophoresis and Western blot analysis                    
8. Histology                                   
9. In vitro capillary formation assay                         
10. In vitro migration assay                        
11. Statistical analysis                         
12. Preparation of buffers, solutions 
 
IV. Results  
 
IV.1. Characterization of MSCs and tumour cell lines  
 
All types of MSCs used in this study: wild type (wtMSC), Gal-1 knocked down (siMSC), 
control cells transfected with scrambled RNA (scMSC) and Gal-1 knockout (MSC 
Gal-1-/-)
 cells 
uniformly expressed CD44, CD73, CD90 and Sca-1 but not markers of hematopoietic cell 
origin, CD34, CD45R, Ly6G, CD3, CD11b, TER119 and differentiated into adipogenic and 
osteogenic directions. Western blotting analysis showed that wt and scMSCs expressed 
abundant, siMSCs low level and MSC 
Gal-1-/-
 none of Gal-1. Tumour cell lines, 4T1 breast 
carcinoma and B16F10 melanoma cells also expressed high level of Gal-1. 
 
IV.2. MSCs localize within the tumour tissue irrespective of their Gal-1 production 
 
To determine whether Gal-1 expression in MSCs contributed to the localization and survival 
of MSCs within the tumour environment, first an in vitro migration assay was carried out. 
Neither absence of Gal-1 in MSC
Gal-1-/-
 nor reduction of Gal-1 in siMSCs affected the number 
of the migrating cells toward 4T1 cells. In contrast, the migration of MSCs significantly 
slowed down. There was no migration observed when MSCs were cultured alone in the 
migration plate. Analysis of the frozen tumour tissue sections obtained from animals 
coinjected with 4T1 breast carcinoma cells and fluorescent dye labelled wtMSCs or MSC
Gal-1-
/-
 showed no difference between the localization of the different MSCs. The siMSCs and 
scMSCs persisted in the tumour similarly to wtMSCs. 
 
IV.3. Gal-1-dependent enhancement of tumour growth 
 
Balb/C mice were injected with syngeneic 4T1 breast carcinoma cells with or without 
wtMSCs or MSCs 
Gal-1-/-
. Tumour volume and weights were increased 3.5-fold and 4-5-fold, 
respectively by wtMSCs on the 40th day and the tumours were palpable much earlier (20th 
versus 32nd day) compared to that of induced by tumour cells alone. In contrast to wild type 
MSCs, co-injection of Gal-1 deficient MSC did not affect tumour development either in size, 
timing, or weight. Co-injection of siMSCs expressing low but detectable amount of Gal-1 or 
control scMSCs resulted in similar effects to that of wtMSCs indicating that low amount of 
Gal-1 in MSCs was sufficient to exert tumour promoting effect. MSCs alone did not generate 
tumour development in 110 days follow up. 
Analysis of incidence of palpable tumour showed that all mice, co-administered with 4T1 and 
wtMSC, developed tumours within 18 days. Nevertheless, injection of 4T1 alone or in 
combination with MSCs 
Gal-1-/-
 showed delayed tumour growth occurring between 21-32 days 
after initiation of the tumour. Evaluation of the animals’ survival showed good correlation 
with the results of tumour incidence since all mice injected with 4T1 and wtMSC died within 




 died between 45 and 85 days 
after tumour initiation. Moreover 1 and 2 animals survived over 110 days in the groups 
injected with 4T1 and MSCs 
Gal-1-/-
 and 4T1 alone, respectively. 
 
IV.4. MSC-induced elevation of microvessel density of primary tumours requires Gal-1 
expression by MSCs 
 
Whether Gal-1 was implicated in MSC-regulated tumour vascularisation, an in vitro capillary 
assay was carried out. The absence of Gal-1 in MSCs resulted in diminished blood vessel-like 
structure formation when co-cultured with H5V murine endothelial cells as compared to the 
effect of wtMSCs. Accordingly, breast carcinoma was vascularised similarly when tumour 
cells were applied alone or together with MSC
Gal-1-/-
. In contrast, wtMSCs dramatically 
increased the vascularisation of the tumour. These results strongly indicated that Gal-1 in 
MSCs played an essential role in generating new capillary networks of the tumours. 
 
IV.5. Gal-1 in MSCs is an important factor in promotion of tumour metastasis  
To determine the role of Gal-1 expression in MSCs regarding the frequency of lung 
metastasis, the lungs of differently treated animals were macroscopically surveyed after 
sacrificing them. Average lung weights were around 250 mg in all experimental groups, 
except those from mice co-injected with 4T1 and wtMSCs which was significantly higher. 
Moreover, co-transplantation of wtMSCs resulted in a significant elevation of the number of 
lung metastatic nodules compared to that induced with MSC 
Gal-1-/-
 or tumour cells alone. 
Decrease of Gal-1 production in siMSCs caused some but not significant change in the 
number of lung metastatic nodules. Accordingly, histochemical analysis of the lung tissues 
showed that the ratio of the metastatic area versus the whole lung section isolated from 
wtMSCs co-injected animals were much higher than in lungs of animals transplanted with 
tumour cells alone or in combination with MSC
Gal-1-/-
. These results implied that Gal-1 
expression in MSCs was critical in promoting metastasis. 
 
IV.6. Tumorigenic effect of endogenous Gal-1 versus MSC-derived Gal-1  
To find out whether endogenous Gal-1 affected tumour growth we changed breast carcinoma 
to melanoma model to be able to use syngeneic tumour conditions. Wild type (wt) C57BL/6 
or Gal-1 knockout (Gal-1-/-) B6.Cg-Lgals1t
m1Rob
/J mice were treated with syngeneic B16F10 
melanoma cells with or without wtMSCs or MSCs 
Gal-1-/-
. Hardly detectable tumours were 
observed when Gal-1-/- mice were injected with melanoma cells alone compared to wt 
animals on the 24th day of injection. Co-transplantation of wtMSCs with tumour cells 
accelerated tumour development in wild type mice although the enhancement was not 
statistically significant in contrast to growth promoting effect of wtMSCs on the growth of 
breast carcinoma. The difference between the two tumour types could be attributed to the 
extremely high aggressiveness of melanoma. More importantly wtMSCs significantly and 
dramatically supported melanoma growth in Gal-1-/- mice. In contrast, transplantation of 
tumour cells together with MSCs 
Gal-1-/-
 did not promote tumour appearance until the 23rd day 
in Gal-1 knockout mice. The presence of Gal-1 in MSCs seemed to be essential to support 
tumour development in knockout mice and Gal-1 expression in tumour cells was not 
sufficient to entirely by-pass the endogenous Gal-1 deficiency. Accordingly, tumour growth 
was urged in Gal-1-/- mice injected with tumour together with wtMSCs, resulting in no 
tumour free animals within 21 days after transplantation. Those Gal-1 knockout animals 
which were injected with tumour cells alone or in the presence of Gal-1 deficient MSCs 
showed a delayed tumour growth as the first animals developed visible tumours on the 21st 
and 25th day and even after 60 days of observation one and two animals remained tumour 
free, respectively. Co-application of wtMSCs in wt mice hardly influenced the appearance of 




Bone marrow derived mesenchymal stem cells (MSCs) have recently been implicated 
as one source of the tumour-associated stroma which plays essential role in regulating tumour 
progression. In spite of the intensive research, the individual factors in MSCs controlling 
tumour progression have not been adequately defined. In the present study we have examined 
the role of galectin-1 (Gal-1), a protein highly expressed in tumours with poor prognosis, in 
MSCs in the course of tumour development. These results confirm that galectin-1 is one of 
the critical factors in MSCs regulating tumour progression. 
 Co-transplantation of wild type MSCs with 4T1 mouse breast carcinoma cells 
enhances the incidence of palpable tumours, growth, vascularisation and metastasis. It 
also reduces survival compared to animals treated with tumour cells alone or in 
combination with Gal-1 knockout MSCs.  
 In vitro studies show that the absence of Gal-1 in MSCs does not affect the number but 
reduces the migration distance of migrating MSCs toward the tumour cells. 
Expression of Gal-1 in MSCs does not effect their localization in the tumour tissue in 
vivo,  
 MSC-derived Gal-1 enhances tumour vascularisation in vivo and induces capillary-
formation when co-cultured with H5V endothelial cells in vitro.   
 Vital role of Gal-1 in MSCs has been further verified in Gal-1 knockout mice. By 
administering B16F10 melanoma cells into Gal-1 deficient animals, tumour growth is 
highly reduced compared to wild type animals. Nevertheless, co-injection of wild type 
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